Rani Therapeutics Holdings, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
RANI$0.55+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements (Unaudited)Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $10,111 | $3,762 |
| Accounts receivable | 600 | — |
| Contract asset | — | 428 |
| Marketable securities | 5,742 | 23,877 |
| Prepaid expenses and other current assets | 1,330 | 1,677 |
| Total current assets | 17,783 | 29,744 |
| Property and equipment, net | 1,348 | 1,548 |
| Operating lease right-of-use asset | 4,748 | 5,096 |
| Other assets | 246 | 246 |
| Total assets | $24,125 | $36,634 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,520 | $1,359 |
| Accrued expenses and other current liabilities | 2,285 | 2,073 |
| Current portion of long-term debt | 15,000 | 15,000 |
| Current portion of operating lease liability | 1,325 | 1,459 |
| Total current liabilities | 20,130 | 19,891 |
| Long-term debt, less current portion | 5,921 | 9,613 |
| Operating lease liability, less current portion | 3,423 | 3,637 |
| Total liabilities | 29,474 | 33,141 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of March 31, 2025 and December 31, 2024 | — | — |
| Class A common stock, $0.0001 par value - 800,000 shares authorized; 33,570 and 33,430 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 3 | 3 |
| Class B common stock, $0.0001 par value - 40,000 shares authorized; 23,972 issued and outstanding as of March 31, 2025 and December 31, 2024 | 2 | 2 |
| Class C common stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of March 31, 2025 and December 31, 2024 | — | — |
| Additional paid-in capital | 107,108 | 104,889 |
| Accumulated other comprehensive gain | 2 | 5 |
| Accumulated deficit | (110,171) | (102,907) |
| Total stockholders' (deficit)/equity attributable to Rani Therapeutics Holdings, Inc. | (3,056) | 1,992 |
| Non-controlling interest | (2,293) | 1,501 |
| Total stockholders' (deficit)/equity | (5,349) | 3,493 |
| Total liabilities and stockholders' equity | $24,125 | $36,634 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.